Philip Hampton has overseen plenty of change in that brief time. For CEO and Hampton appointee Emma Walmsley, a change at the top should bring fresh pressure to deliver. Hampton came aboard at a time of mounting investor discontent with the old regime of chairman Chris Gent and CEO Andrew Witty.

Philip Hampton has overseen plenty of change in that brief time. For CEO and Hampton appointee Emma Walmsley, a change at the top should bring fresh pressure to deliver. Hampton came aboard at a time of mounting investor discontent with the old regime of chairman Chris Gent and CEO Andrew Witty.

Diners will not wait one-and-a-half hours for a takeaway to deliver, according to YouGov research. So why did takeaway food service Just Eat think investors might wait one-and-a-half years? That was the ...

The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.

The search for Sir Philip’s successor will take up to nine months, according to someone familiar with the process, who said he would have completed about five years on the board when he eventually stepped down. On Monday shareholders said his successor should be someone adept in change management, perhaps having already overseen a merger or demerger, since the strategic “heavy lifting” had taken place on Sir Philip’s watch and a different set of skills was now required. One top-10 shareholder suggested it was crucial to ensure that the pharma business developed into “a self-funding entity” within the three-year timeframe set for the break-up.

It's not too late to late to buy the banks, even after today's monster run, Jim Cramer told his Mad Money viewers Wednesday. In short, the banks are making more money than ever, Cramer said, and they're doing it with more technology and fewer employees. The fact is, shares of Goldman should never have been that low in the first place, Cramer said.

Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

In this daily bar chart of GSK, below, we can see a choppy sideways trading range for GSK the past year. The daily On-Balance-Volume (OBV) line has turned to the upside signaling that buyers of GSK have turned more aggressive. In the middle of December we can see that the Moving Average Convergence Divergence (MACD) oscillator crossed to the upside for a cover shorts buy signal.

Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco. Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020. On the company's portfolio of cancer medicines, she said GlaxoSmithKline had almost doubled the size of its immuno-oncology pipeline over the past few months.

GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker's chief executive officer said on Tuesday. Britain's biggest drugmaker is also likely to evaluate licensing deals and would continue to invest in early-stage HIV treatments, CEO Emma Walmsley said at the JP Morgan healthcare conference in San Francisco. Walmsley said the company had extensive plans for its experimental drug to treat multiple myeloma, which targets a protein called BCMA, adding that it could be launched by 2020.